Evidence map›Paper›PMID 34077724›Full record

ArticleCell reports2021

Type I interferon decreases macrophage energy metabolism during mycobacterial infection.

Gregory S Olson, Tara A Murray, Ana N Jahn, Dat Mai, Alan H Diercks, Elizabeth S Gold, Alan Aderem

Open access · goldAbstract read
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 92 papers.

0numbers the graph read from it
0cells of the map it votes in
92citing papers in PubMed
7.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

92 citing papers in PubMed, 129 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Restricted MHC-II trafficking inbioRxiv : the preprint server for biology · 2026
    Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. HAPI Cells are SIM-A9-related Mouse Microglial Cells Useful forbioRxiv : the preprint server for biology · 2026
    Article
  17. Article
  18. Review
  19. Article
  20. Review

32 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Gregory S OlsonCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA; Medical Scientist Training Program, University of Washington School of Medicine, Seattle, WA 98195, USA.
Tara A MurrayCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Ana N JahnCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Dat MaiCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Alan H DiercksCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA.
Elizabeth S GoldCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA; Department of Cardiology, Virginia Mason, Seattle, WA 98101, USA. Electronic address: elizabeth.gold@seattlechildrens.org.
Alan AderemCenter for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle, WA 98109, USA; Department of Immunology, University of Washington School of Medicine, Seattle, WA 98195, USA.
Infectious Disease Research Institute · USCenter for Infectious Disease Research · US

Funding

IMMUNE MECHANISMS OF PROTECTION AGAINST MYCOBACTERIUM TUBERCULOSIS CENTER (IMPAC-TB) - SARS-CoV-2 RELATED RESEARCH75N93019C00070 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI URDAHL, KEVIN · 2019 to 2025
$86.6M
Systems Biology CoreU19AI100627 · NIAID · SCRIPPS RESEARCH INSTITUTE, THE · PI NOLAN, GARRY P · 2012 to 2021
$49.1M
Technology CoreU19AI135976 · NIAID · SEATTLE CHILDREN'S HOSPITAL · PI ADEREM, ALAN A · 2018 to 2022
$17.0M
LPS Signaling in Macrophages: The Roll of TollR01AI032972 · NIAID · UNIVERSITY OF WASHINGTON · PI ADEREM, ALAN A · 1992 to 2020
$14.6M
NIAID NIH HHS 75N93019C00070NIAID NIH HHS R01 AI032972NIAID NIH HHS U19 AI100627NIAID NIH HHS U19 AI135976
6 · The paper itself

Abstract

Metabolic reprogramming powers and polarizes macrophage functions, but the nature and regulation of this response during infection with pathogens remain controversial. In this study, we characterize the metabolic and transcriptional responses of murine macrophages to Mycobacterium tuberculosis (Mtb) in order to disentangle the underlying mechanisms. We find that type I interferon (IFN) signaling correlates with the decreased glycolysis and mitochondrial damage that is induced by live, but not killed, Mtb. Macrophages lacking the type I IFN receptor (IFNAR) maintain glycolytic flux and mitochondrial function during Mtb infection in vitro and in vivo. IFNβ itself restrains the glycolytic shift of inflammatory macrophages and initiates mitochondrial stress. We confirm that type I IFN acts upstream of mitochondrial damage using macrophages lacking the protein STING. We suggest that a type I IFN-mitochondrial feedback loop controls macrophage responses to mycobacteria and that this could contribute to pathogenesis across a range of diseases.

Indexed as

Energy MetabolismAnimalsGlycolysisHot TemperatureInterferon Type IMacrophagesMembrane ProteinsMiceMitochondriaMycobacterium tuberculosisSignal TransductionSTING ProteinStress, PhysiologicalTranscription, GeneticTuberculosisInterferon Type IMembrane ProteinsSting1 protein, mouseSTING ProteinimmunometabolismmacrophagemitochondriamycobacteriaSTINGtuberculosistype I interferon

Identifiers

PMID34077724
PMCPMC8244443
OpenAlexW3165160504

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.